Cargando…
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
Liposomal amphotericin B is a “true” liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnosti...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269132/ https://www.ncbi.nlm.nih.gov/pubmed/22294858 http://dx.doi.org/10.2147/IDR.S22587 |
_version_ | 1782222451871055872 |
---|---|
author | Miceli, Marisa H Chandrasekar, Pranatharthi |
author_facet | Miceli, Marisa H Chandrasekar, Pranatharthi |
author_sort | Miceli, Marisa H |
collection | PubMed |
description | Liposomal amphotericin B is a “true” liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnostic capability of invasive fungal infections, most clinicians are often compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues to play an important role in the empiric management of invasive fungal infections, despite the recent availability of several other drugs in the azole and echinocandin classes. |
format | Online Article Text |
id | pubmed-3269132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32691322012-01-31 Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients Miceli, Marisa H Chandrasekar, Pranatharthi Infect Drug Resist Review Liposomal amphotericin B is a “true” liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnostic capability of invasive fungal infections, most clinicians are often compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues to play an important role in the empiric management of invasive fungal infections, despite the recent availability of several other drugs in the azole and echinocandin classes. Dove Medical Press 2012-01-11 /pmc/articles/PMC3269132/ /pubmed/22294858 http://dx.doi.org/10.2147/IDR.S22587 Text en © 2012 Miceli and Chandrasekar, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Miceli, Marisa H Chandrasekar, Pranatharthi Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients |
title | Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients |
title_full | Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients |
title_fullStr | Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients |
title_full_unstemmed | Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients |
title_short | Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients |
title_sort | safety and efficacy of liposomal amphotericin b for the empirical therapy of invasive fungal infections in immunocompromised patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269132/ https://www.ncbi.nlm.nih.gov/pubmed/22294858 http://dx.doi.org/10.2147/IDR.S22587 |
work_keys_str_mv | AT micelimarisah safetyandefficacyofliposomalamphotericinbfortheempiricaltherapyofinvasivefungalinfectionsinimmunocompromisedpatients AT chandrasekarpranatharthi safetyandefficacyofliposomalamphotericinbfortheempiricaltherapyofinvasivefungalinfectionsinimmunocompromisedpatients |